While we are waiting for new data, we can console ourselves that we are not the only people who believe in the potential of IMU. Those that are confused by the data from the US trial preceeding the Azer-cel 1b trial can confirm also in this Analyst coverage their were 2CRs in the Azer-cel cohort B with IL-2 and 1CR in the Cohort A group without IL-2. We are hoping that these CRs have now reached the crucial 6 month sustainability timeframe. The valuation of .49c is in my opinion optimistic, however I would envisage many holders of this company would be over the moon if half this estimated price was achieved.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)